Montelukast Orion (Montelukast Sodium)

The drug blocks the cysteinyl leukotriene receptor CysLT1, preventing leukotriene D4 from binding. This inhibition stops the cascade that causes bronchoconstriction, mucus production and inflammation in the airways and nasal passages.

The appropriate dose is determined by the prescribing clinician based on the patient’s age, weight, indication and clinical response. Dosage may differ for asthma, allergic rhinitis or exercise‑induced bronchoconstriction.

Montelukast is classified as pregnancy category B, indicating no evidence of risk in animal studies and limited human data. It may be used during pregnancy if the potential benefit justifies the risk. While it passes into breast milk in small amounts, breastfeeding mothers should discuss use with their healthcare provider.

To place an order, submit an enquiry on the Montelukast Orion product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Montelukast offers an oral alternative to inhaled corticosteroids and bronchodilators, targeting leukotriene‑driven inflammation rather than directly relaxing airway smooth muscle. It is often used as add‑on therapy for patients who need additional control or cannot tolerate inhaled steroids, but it does not replace rescue bronchodilators for acute attacks.

Store the tablets at ambient temperature, preferably below 25 °C, in the original blister pack or container. Protect them from moisture, direct sunlight and excessive heat to maintain stability throughout the shelf life.

Montelukast Orion is taken orally, usually as a single tablet once daily. It can be swallowed with or without food, according to the prescriber’s instructions.

Serious adverse events include severe allergic reactions such as angioedema or anaphylaxis, mood changes including depression or suicidal thoughts, and significant liver enzyme elevations. Patients should seek immediate medical attention if they experience any of these symptoms.

Montelukast is contraindicated in individuals with known hypersensitivity to montelukast or any of its excipients. Caution is advised for patients with severe hepatic impairment, and it should be used only under medical supervision in those with a history of mood disorders.